SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Mining/Resources >

India Globalization Capital Inc (IGC)

IGC RSS Feed
Add IGC Price Alert      Hide Sticky   Hide Intro
Moderator: NetworkNewsWire
Search This Board: 
Last Post: 12/14/2017 11:49:02 AM - Followers: 97 - Board type: Free - Posts Today: 0

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first-mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio

IGC recently exited its legacy businesses and currently holds international investments in land and in a hotel project.

 

Investment Highlights

• Building a patented portfolio of phytocannabinoid-based pharmaceutical and nutraceutical products for one of the world's fastest growing industries
• Positioning for first-mover advantage by developing novel therapies, applying for patents, and acquiring technologies from related industries
• Strategic alliance with International Pharma Trials provides expertise in the FDA process and pharma-trials

 


Development Pipeline

Through cutting-edge research, IGC is developing a product portfolio of phytocannabinoid-based therapies for the treatment of a wide range of life altering or life threatening indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis.


Target Markets

Attitudes toward cannabis have transformed substantially across the United States. Support for cannabis legalization is rapidly outpacing opposition; 53 percent of Americans believe cannabis should be made legal, compared with 44 percent supporting illegality of cannabis. Within this burgeoning market, IGC has identified key areas to which it can apply its phytocannabinoid-based therapies to address unmet medical needs.

 

Pain

The treatment of pain is a great challenge for health care professionals as it can often debilitate individuals in ways that affect their day-to-day functioning, which significantly impacts the nation's productivity and economy. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion.

A major disadvantage of using currently available drug therapies to treat chronic severe pain is that these opioid based drugs may lead to side effects like hallucinations, constipation, sedation, nausea, respiratory depression, and dysphoria.

IGC-501

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Epilepsy

Approximately 50 million people worldwide are affected by epilepsy (Sanders, 2003), a condition attributed to multiple factors. In dogs and cats, seizures are often caused by abnormal brain activity. They can be subtle or cause violent convulsions. Some seizures only occur once, but repeated seizures require treatment to prevent larger areas of the brain from becoming affected.

IGC-502

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Eating Disorders

Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. Approximately 1.3 million people in the United States are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson's disease, HIV/AIDS, and other progressive illnesses. Notably, cancer-induced anorexia/cachexia is responsible for about 20% of all cancer deaths.

IGC-504 and IGC-506

Indicated for a variety of eating disorders, including cachexia, IGC-504 and IGC 506 are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies. IGC-506 is being developed for both human and veterinary use.

 


Industry Partnerships

IGC has established a strategic alliance with International Pharma Trials, whose doctors and researchers have expertise in disorders of the central and peripheral nervous system as well as expertise in the FDA process and pharma-trials.

The company continues to seek information exchanges with medical cannabis dispensaries, research scientists, doctors, medical and business professionals, and biotech companies working in the cannabinoid space.

Leveraging its business model and collaborative research, IGC can help commercialize products while finding innovative ways of helping patients benefit from cannabinoids.

 


Leadership


Ram Mukunda, President, CEO and Director

Ram Mukunda has served as IGC's executive chairman, chief executive officer, and president since the company's inception on April 29, 2005. From January 1990 to May 2004, Mukunda served as founder, chairman, and chief executive officer of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec was the first pure play international long distance carrier. Mukunda was responsible for organizing, structuring and integrating a number of companies owned by Startec. Under Mukunda's tenure at Startec, the company made an IPO of its equity securities in 1997 on NASDAQ. Prior to Startec, Mr. Mukunda served as Strategic Planning Advisor at Intelsat, a communications satellite services provider.

Mukunda serves as an emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a council member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, the 2013 University of Maryland's International Alumnus of the Year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland.

John Cherin, CFO, Treasurer, PAO

John Cherin is a retired senior executive with international experience in assisting young companies. He has provided insight to top management and Board of Directors on strategic analysis and improvement of operating procedures in financial reporting and operations. From 1966 to 1997, Cherin gained his experience as a senior partner at Arthur Andersen while managing practices aimed at businesses in the US and overseas. In addition he founded and managed Cherin Global Consulting in 1997-2005 and the Cherin Group LLC in 2004 to date. He also served as CFO for IGC in its formative stages for the purpose of raising capital to enable IGC's launch in the post startup phase.

Cherin is a retired CPA, a graduate of Northeastern University class of 1966 and in 1967 was the Silver Medal Recipient from the Massachusetts Society of CPAs.

Claudia Grimaldi, General Manager, Director of Cabaran Ultima

Claudia Grimaldi is the general manager and director of IGC's project development and managing company in Malaysia. Grimaldi is responsible for coordinating the staff in various countries and ensuring timely and accurate regulatory compliance and statutory reporting. Prior to assuming her current role in 2013, she spent three years managing the office of the CEO.

Prior to IGC, Grimaldi worked in human resources and psychotherapy. She graduated Summa Cum Laude from Javeriana University, a top five University in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College. Grimaldi is a member of Delta Mu Delta International Honor Society. She is also fluent in both English and Spanish.

 


India Globalization Capital
PO BOX 60642
Potomac, MD 20859-0642
Phone: (301) 983-0998
www.IGCinc.us

NetworkNewsWire
1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217
www.NetworkNewsWire.com

 

NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/

SureTrader
Interactive Brokers Advertisement
IGC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IGC News: Statement of Changes in Beneficial Ownership (4) 12/08/2017 05:53:57 PM
IGC News: Report of Proposed Sale of Securities (144) 12/07/2017 05:28:43 PM
IGC News: Statement of Changes in Beneficial Ownership (4) 12/05/2017 06:49:57 PM
IGC News: Statement of Changes in Beneficial Ownership (4) 12/05/2017 06:47:18 PM
IGC News: Current Report Filing (8-k) 11/30/2017 06:05:33 AM
News News Alert: India Globalization Capital Provides Update on Hyalolex for Alzheimer’s Commercialization Strategy 12/14/2017 08:00:00 AM
PostSubject
#5218   IGC Issues Update on Efforts to Roll Out NetworkNewsWire 12/14/17 11:49:02 AM
#5217   IGC expects to raise money for the canna-pharmaceutical JohnCM 12/14/17 02:34:44 AM
#5216   https://goo.gl/maps/vMkjFEE1sMu JohnCM 12/14/17 02:21:14 AM
#5215   Only run up by the hired broker so Sprycel 12/12/17 10:13:19 AM
#5214   TIME TO SHORT all4weed 12/11/17 05:51:57 PM
#5213   This company has bought Patent and nothing else, all4weed 12/11/17 05:49:12 PM
#5212   Completely agree, no one seem to be bothered all4weed 12/11/17 05:34:54 PM
#5211   Ready n hoping best NYSE stock to pwn now devilskyvin 12/08/17 12:15:47 PM
#5210   * * $IGC Video Chart 12-07-17 * * ClayTrader 12/07/17 04:13:23 PM
#5209   Kinda quiet huh? IGC's almost $1 a share now Smilin_B 12/07/17 10:49:25 AM
#5208   IGC Launches Pharmaceutical Cannabinoid Pipeline Websites NetworkNewsWire 12/07/17 10:47:58 AM
#5207   Chart looks good. Flagging below $1 INTL 12/07/17 10:40:45 AM
#5206   This is scam not a company. Why is california007 12/07/17 09:24:56 AM
#5205   I was wondering the same thing! Looks like Bossman1981 12/06/17 10:21:18 PM
#5204   * * $IGC Video Chart 12-06-17 * * ClayTrader 12/06/17 05:19:54 PM
#5203   So why is this taking off today? SgtJBone 12/06/17 02:21:37 PM
#5202   AND THE INSIDERS JUST KEEP SELLING THEIR FREE Sprycel 12/05/17 08:55:39 PM
#5201   IGC's Future Business Strategy NetworkNewsWire 11/30/17 03:47:38 PM
#5200   IGC Enters MOU for Distribution in Germany, Plans NetworkNewsWire 11/29/17 09:42:41 AM
#5199   IGC Reports Q2 2018 Financial Results NetworkNewsWire 11/20/17 10:16:38 AM
#5198   IGC buy 0.5049 stocktrademan 11/16/17 01:33:48 PM
#5197   IGC Releases Results of Annual Shareholders Meeting NetworkNewsWire 11/14/17 02:51:38 PM
#5196   IGC Regains Listing Compliance NetworkNewsWire 11/10/17 09:58:52 AM
#5195   IGC Avoids Regulatory Costs through Cannabis-based Drug Candidates NetworkNewsWire 11/06/17 12:14:00 PM
#5194   Ceo just sold 250,000 shares and u suckers @WolfofWeedST 11/06/17 10:40:42 AM
#5193   IGC Targets Multiple Health Concerns with Cannabis-based Therapies NetworkNewsWire 11/02/17 02:34:42 PM
#5192   IGC Aims to Fast-Track Release of Hyalolex in NetworkNewsWire 11/02/17 02:30:51 PM
#5191   It's payroll time for RAM THE SCAM! Sprycel 11/01/17 10:31:52 AM
#5190   Leaders in Medical Marijuana and the Global Alzheimer’s Markets NetworkNewsWire 10/31/17 08:48:18 AM
#5189   I agree 100%. In fact this stock Sprycel 10/29/17 08:44:48 PM
#5188   Pray tell us why this isnt a .000x Smilin_B 10/29/17 07:06:35 PM
#5187   This company has NO revenue, NONE but yet Sprycel 10/29/17 05:56:39 PM
#5186   Interesting thought...... bigone 10/27/17 09:44:21 PM
#5185   Hell no... why when they can just wait @WolfofWeedST 10/27/17 12:13:34 AM
#5184   IGC Could Release Potential Blockbuster Alzheimer’s Treatment in NetworkNewsWire 10/25/17 02:19:38 PM
#5183   IGC Enters MOU Related to Import and Distribution NetworkNewsWire 10/25/17 09:31:43 AM
#5182   I am not quit ready to jump in bigone 10/23/17 04:17:36 PM
#5181   Not that I'm aware of. Just posting what chattsy11 10/22/17 10:02:59 PM
#5180   Is this paid advertising for the company by bigone 10/22/17 09:49:12 PM
#5179   Is this paid advertising for the company by bigone 10/22/17 09:49:12 PM
#5178   https://finance.yahoo.com/news/seethruequity-issues-note-india-globalization-130 chattsy11 10/22/17 02:06:31 PM
#5177   THANK YOU FOR THE BACKGROUND. bigone 10/21/17 11:07:16 PM
#5176   All I got was financial news would be chattsy11 10/21/17 10:00:22 PM
#5175   IGC What is the news? Chart has room INTL 10/21/17 09:47:15 PM
#5174   News out. Monday before open financials will be out. chattsy11 10/20/17 10:57:54 PM
#5173   This stock has been nothing less than a Sprycel 10/20/17 05:54:48 PM
#5172   Might some drug distribution company partner with them? bigone 10/20/17 05:18:44 PM
#5171   SeeThruEquity Issues $1.20 Price Target on India Globalization Capital jcamp212 10/20/17 10:22:43 AM
#5170   No way this is possible... comes down to @WolfofWeedST 10/19/17 01:03:44 PM
#5169   IGC - Worth a look, commercialization early 2018 akaWillyWonka 10/18/17 10:33:47 AM
PostSubject